Loading…
20,252 grants found
Showing 19,541 – 19,560 of 20,252 grants
ABSTRACT.Genomic deletions of major tumor suppressor genes are frequent events in cancer yet presently remain therapeutically unactionable for the purpose of precision oncology.Our...
Project Summary/Abstract Despite the significant advances in therapy development, a large proportion of hematological malignancies, especially the aggressive types remain incurable...
ABSTRACT. Genomic deletions of major tumor suppressor genes are frequent events in cancer yet presently remain therapeutically unactionable for the purpose of precision oncology. O...
Project Summary/Abstract Despite the significant advances in therapy development, a large proportion of hematological malignancies, especially the aggressive types remain incurable...
ABSTRACT. Genomic deletions of major tumor suppressor genes are frequent events in cancer yet presently remain therapeutically unactionable for the purpose of precision oncology. O...
ABSTRACT. Genomic deletions of major tumor suppressor genes are frequent events in cancer yet presently remain therapeutically unactionable for the purpose of precision oncology. O...
PROJECT SUMMARY Acute Myeloid Leukemia (AML) is a lethal blood cancer, with a 5-year survival rate of only 25%. One driver of especially poor prognosis in AML is mutation of Colony...
Prostate cancer is the most common cancer in the US male population, with an estimated 160,000 new cases in 2018.Treatment with radical prostatectomy (RP), complete surgical excisi...
ABSTRACT Endometrial cancer (EC) is the most common gynecologic cancer in the US.Incidence is increasing, especially for aggressive, understudied tumors that confer poor prognosis...
ABSTRACT PD-1-directed immune checkpoint inhibitors (ICI) have significantly improved survival in metastatic melanoma compared to traditional chemotherapy. Unfortunately, less than...
The Fearon and Vogelstein multistep cancer progression model of colon cancer defines key genetic changes associated with progression from normal colorectal tissue to early/late ade...
PROJECT SUMMARY Acute Myeloid Leukemia (AML) is a lethal blood cancer, with a 5-year survival rate of only 25%. One driver of especially poor prognosis in AML is mutation of Colony...
Prostate cancer is the most common cancer in the US male population, with an estimated 160,000 new cases in 2018. Treatment with radical prostatectomy (RP), complete surgical excis...
ABSTRACT Endometrial cancer (EC) is the most common gynecologic cancer in the US. Incidence is increasing, especially for aggressive, understudied tumors that confer poor prognosis...
ABSTRACT PD-1-directed immune checkpoint inhibitors (ICI) have significantly improved survival in metastatic melanoma compared to traditional chemotherapy. Unfortunately, less than...
Prostate cancer is the most common cancer in the US male population, with an estimated 160,000 new cases in 2018. Treatment with radical prostatectomy (RP), complete surgical excis...
PROJECT SUMMARY Acute Myeloid Leukemia (AML) is a lethal blood cancer, with a 5-year survival rate of only 25%. One driver of especially poor prognosis in AML is mutation of Colony...
The Fearon and Vogelstein multistep cancer progression model of colon cancer defines key genetic changes associated with progression from normal colorectal tissue to early/late ade...
Prostate cancer is the most common cancer in the US male population, with an estimated 160,000 new cases in 2018. Treatment with radical prostatectomy (RP), complete surgical excis...
PROJECT SUMMARY Acute Myeloid Leukemia (AML) is a lethal blood cancer, with a 5-year survival rate of only 25%. One driver of especially poor prognosis in AML is mutation of Colony...